OBJECTIVE: Islet allotransplantation is a less invasive alternative to surgical pancreas transplantation for Type 1 diabetes, while percutaneous intraportal islet autotransplantation (PIPIAT) is usually performed after pancreatic surgery to prevent diabetes. Our aim was to assess the feasibility, radiological aspects, complications and clinical outcome of PIPIAT following pancreatic surgery for not only chronic pancreatitis but also benign and malignant nodules. METHODS: From 2008 to 2012, 41 patients were enrolled for PIPIAT 12-48 h after pancreatic surgery (extended pancreatic surgery for chronic pancreatitis and benign/malignant neoplasms). PIPIAT was performed using a combined ultrasonography and fluoroscopy-guided technique (4-F catheter). PIPIAT feasibility, median follow-up and metabolic (insulin independence rate, graft function based on C-peptide levels) and oncologic outcomes were recorded. RESULTS: PIPIAT was not performed in 7/41 patients (4 cases for an inadequate islet mass, 2 cases for haemodynamic instability and 1 case for islet culture contamination), while it was successfully performed in 34/34 patients. Procedure-related major complications occurred in four patients: two bleedings requiring transfusions, one patient with left portal vein thrombosis and one patient with sepsis. Median follow-up duration was 546 days. Insulin independence was achieved in 15/34 (44%) patients, partial graft function in 16/34 (47%) patients and no function in 3/34 (9%) patients. None of the 17 patients with malignant nodules developed liver metastases during follow-up. CONCLUSION: PIPIAT, performed under ultrasound and fluoroscopy combined guidance and not requiring immunosuppression, is feasible, with a relatively low complication rate and a better metabolic outcome than allotransplantation. ADVANCES IN KNOWLEDGE: PIPIAT can prevent pancreatogenic diabetes. Ultrasound is a useful tool for the guidance and monitoring of PIPIAT.
OBJECTIVE: Islet allotransplantation is a less invasive alternative to surgical pancreas transplantation for Type 1 diabetes, while percutaneous intraportal islet autotransplantation (PIPIAT) is usually performed after pancreatic surgery to prevent diabetes. Our aim was to assess the feasibility, radiological aspects, complications and clinical outcome of PIPIAT following pancreatic surgery for not only chronic pancreatitis but also benign and malignant nodules. METHODS: From 2008 to 2012, 41 patients were enrolled for PIPIAT 12-48 h after pancreatic surgery (extended pancreatic surgery for chronic pancreatitis and benign/malignant neoplasms). PIPIAT was performed using a combined ultrasonography and fluoroscopy-guided technique (4-F catheter). PIPIAT feasibility, median follow-up and metabolic (insulin independence rate, graft function based on C-peptide levels) and oncologic outcomes were recorded. RESULTS: PIPIAT was not performed in 7/41 patients (4 cases for an inadequate islet mass, 2 cases for haemodynamic instability and 1 case for islet culture contamination), while it was successfully performed in 34/34 patients. Procedure-related major complications occurred in four patients: two bleedings requiring transfusions, one patient with left portal vein thrombosis and one patient with sepsis. Median follow-up duration was 546 days. Insulin independence was achieved in 15/34 (44%) patients, partial graft function in 16/34 (47%) patients and no function in 3/34 (9%) patients. None of the 17 patients with malignant nodules developed liver metastases during follow-up. CONCLUSION: PIPIAT, performed under ultrasound and fluoroscopy combined guidance and not requiring immunosuppression, is feasible, with a relatively low complication rate and a better metabolic outcome than allotransplantation. ADVANCES IN KNOWLEDGE: PIPIAT can prevent pancreatogenic diabetes. Ultrasound is a useful tool for the guidance and monitoring of PIPIAT.
Authors: David E R Sutherland; David M Radosevich; Melena D Bellin; Bernard J Hering; Gregory J Beilman; Ty B Dunn; Srinath Chinnakotla; Selwyn M Vickers; Barbara Bland; A N Balamurugan; Martin L Freeman; Timothy L Pruett Journal: J Am Coll Surg Date: 2012-03-06 Impact factor: 6.113
Authors: Paolo Fiorina; Massimo Venturini; Franco Folli; Claudio Losio; Paola Maffi; Claudia Placidi; Stefano La Rosa; Elena Orsenigo; Carlo Socci; Carlo Capella; Alessandro Del Maschio; Antonio Secchi Journal: Diabetes Care Date: 2005-06 Impact factor: 19.112
Authors: Y F Smets; R G Westendorp; J W van der Pijl; F T de Charro; J Ringers; J W de Fijter; H H Lemkes Journal: Lancet Date: 1999-06-05 Impact factor: 79.321
Authors: Ravi Bhargava; Peter A Senior; Thomas E Ackerman; Edmond A Ryan; Breay W Paty; Jonathan R T Lakey; A M James Shapiro Journal: Diabetes Date: 2004-05 Impact factor: 9.461
Authors: Pablo Cure; Antonello Pileggi; Tatiana Froud; Shari Messinger; Raquel N Faradji; David A Baidal; Roberta Cardani; Andrea Curry; Raffaella Poggioli; Alberto Pugliese; Arthur Betancourt; Violet Esquenazi; Gaetano Ciancio; Gennaro Selvaggi; George W Burke; Camillo Ricordi; Rodolfo Alejandro Journal: Transplantation Date: 2008-03-27 Impact factor: 4.939